# OnCo record letrozole (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/letrozole/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "letrozole" ;
  schema:name "Letrozole (and other aromatase inhibitors)"@en ;
  schema:description "Daily pills that stop the body making oestrogen after menopause, the backbone of hormone therapy for most breast cancers."@en ;
  schema:url <https://onco.cc/drugs/letrozole/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Letrozole> ;
  owl:sameAs <http://www.wikidata.org/entity/Q194974> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Letrozole> ;
  onco:status "approved" ;
  onco:modality "Small-molecule aromatase inhibitor" ;
  schema:alternateName "Femara; anastrozole (Arimidex); exemestane (Aromasin)" ;
  onco:approval "US 1997: Advanced breast cancer after tamoxifen (letrozole)", "US 2005: Adjuvant early breast cancer (letrozole)" ;
  onco:acceleratedApproval "US 2004-10-29: Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen", "US 2005-12-28: Postmenopausal women with HR positive early breast cancer" ;
  onco:acceleratedApprovalConfirmed "US 2010-04-30: Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen", "US 2010-04-30: Postmenopausal women with HR positive early breast cancer" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/granulosa-cell-tumour/>, <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/> ;
  onco:terms <https://onco.cc/terms/lgsoc/> ;
  onco:trials <https://onco.cc/trials/soft-text/>, <https://onco.cc/trials/monaleesa-2/>, <https://onco.cc/trials/paloma-2/>, <https://onco.cc/trials/monarch-3/>, <https://onco.cc/trials/nct06072781/>, <https://onco.cc/trials/nct04557449/>, <https://onco.cc/trials/nct04553133/>, <https://onco.cc/trials/nct04606446/>, <https://onco.cc/trials/nct07288359/>, <https://onco.cc/trials/nct05867251/> .